Absence of nuclear receptors LXRs impairs immune response to androgen deprivation and leads to prostate neoplasia.

Version imprimableSend by emailPDF version
Auteur: 
Bousset, L; Septier, A; Bunay, J; Morel, L; Baron, S
Date Publication: 
2020
Mois: 
Décembre
Revue: 
PLoS biology
ISSN: 
1545-7885
NLM-ID: 
101183755
Volume: 
18
Num: 
12
Page: 
e3000948
Résumé: 
Chronic inflammation is now a well-known precursor for cancer development. Infectious prostatitis are the most common causes of prostate inflammation, but emerging evidence points the role of metabolic disorders as a potential source of cancer-related inflammation. Although the widely used treatment for prostate cancer based on androgen deprivation therapy (ADT) effectively decreases tumor size, it also causes profound alterations in immune tumor microenvironment within the prostate. Here, we demonstrate that prostates of a mouse model invalidated for nuclear receptors liver X receptors (LXRs), crucial lipid metabolism and inflammation integrators, respond in an unexpected way to androgen deprivation. Indeed, we observed profound alterations in immune cells composition, which was associated with chronic inflammation of the prostate. This was explained by the recruitment of phagocytosis-deficient macrophages leading to aberrant hyporesponse to castration. This phenotypic alteration was sufficient to allow prostatic neoplasia. Altogether, these data suggest that ADT and inflammation resulting from metabolic alterations interact to promote aberrant proliferation of epithelial prostate cells and development of neoplasia. This raises the question of the benefit of ADT for patients with metabolic disorders.
MeSH: 
Androgen Antagonists/immunology|Androgens/metabolism|Animals|Disease Models, Animal|Immunity/immunology/physiology|Liver X Receptors/genetics/immunology/metabolism|Male|Mice|Mice, 129 Strain|Mice, Inbred C57BL|Neoplasms/etiology/immunology/metabolism|Prostate/metabolism/pathology|Prostatic Neoplasms/metabolism/pathology/therapy|Receptors, Cytoplasmic and Nuclear/metabolism|Tumor Microenvironment
DOI: 
10.1371/journal.pbio.3000948
PMID: 
33284790